Back to search

University of Ioannina

Επίδραση κυτταροστατικών φαρμάκων σε σχήματα προσομοιώσης μετρονομικής θεραπείας σε ανθρώπινα ενδοθηλιακά κύτταρα: in vitro μεταφραστική μελέτη κλινικής εφαρμογής μετρονομικής βινορελμπίνης

Abstract

dc:description

A chemotherapy dosing strategy that attracts growing clinical interest is low dose metronomic chemotherapy. It involves the close, regular administration of conventional chemotherapeutic drugs without prolonged drug free intervals over extended periods of time. In contrast with conventional chemotherapy of maximum tolerated dose (MTD), the primary target of metronomic chemotherapy is thought to be tumor’s neovasculature. Angiogenesis, as the pioneer in the field Judah Folkman suggested in one of his latest papers, plays in cancer the role of ‘organizing principle’ because of its critical role in malignant tumor development. In this context angiogenesis is understood as a tumor supporting process, which is kept up aberrantly active through the influence of counterbalancing proteins that are produced by cancer cells and the microenvironment and drive endothelial cells functional and proliferating. In view of that, antiangiogenic cancer therapy optimally aims to inhibit proliferation and function of activated endothelial cells and thereof tackle cancer progression on a chronic basis. Among different classes of cytotoxics, microtubule disruptors are considered most appropriate for metronomic low-dose antiangiogenic chemotherapy because of their potency to inhibit proliferation and also function of endothelial cells at very low concentrations. Recently, availability of oral formulation of microtubule disrupting vinorelbine (Navelbine Soft Capsules®) led to clinical investigation of this drug at a metronomic dosing schedule [NCT00278070]. In this context we investigated functional and molecular effects of vinorelbine (VRL) against proliferating human umbilical vein endothelial cells (HUVEC) in an experimental in vitro simulation of conventional and metronomic chemotherapy.In regard to induced changes in angiogenesis signaling genes under the influence of protracted and short exposure to VRL we studied interleukin-8 (IL-8), cyclooxygenase-2 (COX-2), thrombospondin-1 (TSP-1), the nuclear peroxisome proliferator-activated receptor gamma (PPARγ) and the cytoplasmic receptors CD36, and finally the transcription factors NF-κB and HIF-1α. Also, we studied the antiproliferative and the molecular effects of rosiglitazone in combination with metronomic vinorelbine on proliferating endothelial cells and investigate the role of PPARγ in the metronomic model.In this study, we used primary human umbilical cord vein (HUVEC) cells, which were isolated from human umbilical cord veins. HUVECs were plated to sub-confluence in plates coated with collagen and treated with VRL, RSG or the combination for 4, 24 and 96hrs. In the 96hr experiment, to simulate a metronomic dosing schedule we replaced the drug-enriched medium every 24hrs. In contrast, the treatment with VRL for 4hrs with a wash out period with drug-free medium for the consecutive 92hrs, and the 24hr time point simulate the classic schedule of chemotherapy with the Maximum Tolerated Dose (MTD). Initially, with the MTS Assay method we investigated the inhibition of cell proliferation and calculated IC50. By qRT-PCR, ELISA and Western blot we measured gene and protein expression of markers of angiogenesis, while with flow cytometry we studied apoptosis and cell cycle of HUVECs.The metronomic administration of vinorelbine was significantly more active in inhibiting proliferation of HUVEC compared to the short exposure with comparative difference of four orders of magnitude (IC50: 1,23nM vs. 32mM). Still, it did not affect cell cycle progression or induced cell apoptosis. Moreover, metronomic vinorelbine was shown to induce the expression of PPARγ and CD36 and inhibit the expression of angiogenic factors such as IL-8 and COX-2.Co-administration of metronomic vinorelbine with rosiglitazone was found to improve the antiangiogenic effects and increase the expression of PPAR even at concentrations previously inhibited his expression. Furthermore, coadministration of the two drugs conserved angiogenic factors in low, basic levels. Finally, synergistic effect of the two drugs was observed in inhibiting proliferation of the endothelial cells.In conclusion, metronomic vinorelbine inhibits proliferation of endothelial cells and suppresses molecular mechanisms of angiogenesis, mainly affecting the expression of PPARγ and IL-8 in enthothelial cells. IL-8 seems to be a metronomic vinorelbine therapy mediator. The activation of the nuclear receptor PPARγ by metronomic chemotherapy opens the way for the creation of co-administration studies of metronomic chemotherapy with activators of PPARγ in order to identify his exact role. Generally, the metronomic chemotherapy emerges as a promising alternative in the treatment of cancer, with satisfactory results. However, many studies are still needed to reveal the mechanisms involved in its anticancer actions.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Biziota, Eirini
  • Μπιζιώτα, Ειρήνη

Subjects

dc:subject × 24

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40971

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Biziota, Eirini; Μπιζιώτα, Ειρήνη. Επίδραση κυτταροστατικών φαρμάκων σε σχήματα προσομοιώσης μετρονομικής θεραπείας σε ανθρώπινα ενδοθηλιακά κύτταρα: in vitro μεταφραστική μελέτη κλινικής εφαρμογής μετρονομικής βινορελμπίνης. University of Ioannina, 2015. http://hdl.handle.net/10442/hedi/40971